

**Supplemental Table 2. Schedule of Safety Evaluations for Pooled Cariprazine Studies RGH-MD-03,
RGH-MD-16, RGH-MD-04, and RGH-MD-05**

Safety Parameter	Screening	Baseline	Double-blind Treatment Phase						Safety Follow-up	
			Weeks							
	-1	0	1	2	3	4	5	6/ET	8/10	
Adverse events			X	X	X	X	X	X	X	
Physical examination	X							X		
Clinical laboratory tests	X			X		X		X		
Prolactin level	X							X		
Vital signs	X	X	X	X	X	X	X	X	X	
12-lead electrocardiogram	X			X		X		X		
Extrapyramidal symptom scales (BARS/AIMS/SAS)		X	X	X	X	X	X	X		
Ophthalmologic examination	X							X		
Pregnancy test	X							X		
C-SSRS	X	X	X	X	X	X	X	X	X	
Concomitant medications	X	X	X	X	X	X	X	X	X	
<p>Assessment weeks differed slightly among studies: In Study RGH-MD-03, clinical laboratory values were assessed at weeks 1, 3, and 6; ophthalmologic examinations were at weeks 0, 8, and 10; and there were 2 follow-up safety visits (some assessments performed at both weeks 8 and 10). Only RGH-MD-04 and RGH-MD-05 included C-SSRS assessment, and there was no ECG assessment at week 4. RGH-MD-16 did not include ophthalmologic examinations.</p> <p>AIMS, Abnormal Involuntary Movement Scale; BARS, Barnes Akathisia Rating Scale; C-SSRS, Columbia-Suicide Severity Rating Scale; ET, early termination; SAS, Simpson-Angus Scale.</p>										